References
- Mariotto AB, Robin Yabroff K, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117–128.
- Glode AE, May MB. Rising cost of cancer pharmaceuticals: cost issues and interventions to control costs. Pharmacother J Human Pharmacol Drug Ther. 2017;37:85–93.
- Howard DH, Bach PB, Berndt ER, et al. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29:139–162.
- Tangka FK, Trogdon JG, Richardson LC, et al. Cancer treatment cost in the United States: has the burden shifted over time? Cancer. 2010;116:3477–3484.
- Kaisaeng N, Harpe SE, Carroll NV. Out-of-pocket costs and oral cancer medication discontinuation in the elderly. J Manag Care Spec Pharm. 2014;20:669–675.
- DeSantis CE, Miller KD, Dale W, et al. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J Clin. 2019;69:452–467.
- President’s Cancer Panel. Promoting value, affordability, and innovation in cancer drug treatment: a report to the president of the United States from the president’s cancer panel. Bethesda, MD: National Institutes of Health, 2018
- Fong JH. Out-of-pocket health spending among medicare beneficiaries: which chronic diseases are most costly? PLOS ONE. 2019;14:e0222539.
- Knight TG, Deal AM, Dusetzina SB, et al. Financial toxicity in adults with cancer: adverse outcomes and noncompliance. J Oncol Pract. 2018;14:e665–e73.
- The Kaiser Family Foundation. National survey of households affected by cancer (2006) https://www.kff.org/health-costs/poll-finding/usa-todaykaiser-family-foundationharvard-school-of-public-2/ (accessed 2021 Apr 20)
- The kaiser family foundation. an overview of medicare (2019) https://www.kff.org/medicare/issue-brief/an-overview-of-medicare/ (accessed 2020 Aug 17)
- Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2017. Bethesda MD: National Institutes of Health; 2020.
- Ogle KS, Swanson GM, Woods N, et al. Cancer and comorbidity: redefining chronic diseases. Cancer. 2000;88:653–663.
- Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29:2534–2542.
- Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32:306–311.
- Doshi JA, Li P, Huo H, et al. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents. J Clin Oncol. 2018;36:476–482.
- Streeter SB, Schwartzberg L, Husain N, et al. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract. 2011;7:46s.
- Nekhlyudov L, Madden J, Graves AJ, et al. Cost-related medication nonadherence and cost-saving strategies used by elderly medicare cancer survivors. J Cancer Surviv. 2011;5:395–404.
- Kennedy JJ, Maciejewski M, Liu D, et al. Cost-related nonadherence in the medicare program: the impact of part D. Med Care. 2011;49:522–526.
- Madden JM, Graves AJ, Zhang F, et al. Cost-related medication nonadherence and spending on basic needs following implementation of medicare part D. JAMA. 2008;299:1922–1928.
- Weaver KE, Rowland JH, Bellizzi KM, et al. Forgoing medical care because of cost: assessing disparities in healthcare access among cancer survivors living in the United States. Cancer. 2010;116:3493–3504.
- Zhang JX, Meltzer DO. Risk factors for cost-related medication non-adherence among older patients with cancer. Integr Cancer Sci Ther. 2015;2:300–304.
- Lee MJ, Khan MM, Salloum RG. Recent trends in cost-related medication nonadherence among cancer survivors in the United States. J Manag Care Spec Pharm. 2018;24:56–64.
- Heisler M, Langa KM, Eby EL, et al. The health effects of restricting prescription medication use because of cost. Med Care. 2004;42:626–634.
- Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421–429.
- Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically iII adults: the treatments people forgo, how often, and who is at risk. Am J Public Health. 2004;94:1782–1787.
- Shih YC, Smieliauskas F, Geynisman DM, et al. Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J Clin Oncol. 2015;33:2190–2196.
- Seiger K, Mostaghimi A, Silk AW, et al. Association of rising cost and use of oral anticancer drugs with Medicare Part D spending from 2013 through 2017. JAMA Oncol. 2019;6:154–156.
- Dusetzina SB, Huskamp HA, Keating NL. Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019. JAMA. 2019;322:2025–2027.
- Paeolella G, Boyd AD, Wirth SM, et al. Adherence to oral anticancer medications: evolving interprofessional roles and pharmacist workforce considerations. Pharmacy (Basel). 2018;6:23.
- The kaiser family foundation. an overview of the medicare part D prescription drug benefit (2020). https://www.kff.org/medicare/fact-sheet/an-overview-of-the-medicare-part-d-prescription-drug-benefit/ (accessed 2021 Aug 25)
- The Kaiser Family Foundation. The out-of-pocket cost burden for specialty drugs in medicare part D in 2019 (2019). https://www.kff.org/medicare/issue-brief/the-out-of-pocket-cost-burden-for-specialty-drugs-in-medicare-part-d-in-2019/ (accessed 2021 Aug 26)
- Yang EJ, Galan E, Thombley R, et al. Changes in drug list prices and amounts paid by patients and insurers. JAMA Network Open. 2020;3:e2028510. Published 2020 Dec 1.
- Yabroff KR, Lund J, Kepka D, et al. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20:2006–2014.
- Pisu M, Azuero A, McNees P, et al. The out of pocket cost of breast cancer survivors: a review. J Cancer Surviv. 2010;4:202–209.
- Pisu M, Henrikson NB, Banegas MP, et al. Costs of cancer along the care continuum: what we can expect based on recent literature. Cancer. 2018;124:4181–4191.
- Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316:858–871.
- Garness K. The challenge of high drug prices in America: cost disclosure in direct-to-consumer advertising may offer a solution. Am Health Drug Benefits. 2019;12:254–255.
- Hernandez I, Good CB, Cutler DM, et al. The contribution of new product entry versus existing product inflation in the rising costs of drugs. Health Aff (Millwood). 2019;38:76–83.
- Geynisman DM, Wickersham KE. Adherence to targeted oral anticancer medications. Discov Med. 2013;15:231–241.
- Trish E, Joyce G, Goldman DP. Specialty drug spending trends among medicare and medicare advantage enrollees, 2007-11. Health Aff (Millwood). 2014;33:2018–2024.
- Cubanski J, Koma W, Neuman T. The out-of-pocket cost burden for specialty drugs in medicare part D in 2019. Kaiser Family Foundation, 2019. https://www.kff.org/medicare/issue-brief/the-out-of-pocket-cost-burden-for-specialty-drugs-in-medicare-part-d-in-2019/ (accessed 2021 Mar 21)
- Sinnott SJ, Buckley C, O’Riordan D, et al. The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. PLOS ONE. 2013;8:e64914.
- Eaddy MT, Cook CL, O’Day K, et al. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T. 2012;37:45–55.
- Chen SY, Shah SN, Lee YC, et al. Moving branded statins to lowest copay tier improves patient adherence. J Manag Care Pharm. 2014;20:34–42.
- Tran G, Zafar SY. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med. 2018;6:166.
- Network for Excellence in Health Innovation. Paying for value: exploring innovative pricing arrangements for biopharmaceuticals. NEHI Issue Brief. 2012. Available from: https://www.nehi-us.org/publications/51-exploring-innovative-pricing-arrangements-for-biopharmaceuticals/view (accessed 2021March 21)
- Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012;87:935–943.
- Park Y, Raza S, George A, et al. The effect of formulary restrictions on patient and payer outcomes: a systematic literature review. J Manag Care Spec Pharm. 2017;23:893–901.
- Shenolikar R, Bruno AS, Eaddy M, et al. Sensitivity of medication use to formulary controls in medicare beneficiaries: a review of the literature. Am Health Drug Benefits. 2011;4:465–474.
- Yarbrough CR. How protected classes in medicare part D influence U.S. drug sales, utilization, and price. Health Econ. 2020;29:608–623.
- Sankaranarayanan J, Collier D, Furasek A, et al. Rurality and other factors associated with adherence to immunosuppressant medications in community-dwelling solid-organ transplant recipients. Res Social Adm Pharm. 2012;8:228–239.